The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Several lines of evidence have suggested that Advanced Glycation End-products (AGEs) play a
role in the development and progression of heart failure. The AGE-crosslink breaker
Alagebrium (ALT-711) improved cardiac function and symptoms in experimental and small human
heart failure studies. These results have not yet been confirmed in a randomized controlled
clinical trial.